Related Experiment Video
Updated: Jul 18, 2026

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
Published on: April 19, 2017
Of yeasts and hyphae: a hematologist's approach to antifungal therapy
1Health Sciences Centre, 820 Sherbrook Street, Winnipeg, Manitoba, Canada. ebow@hsc.mb.ca
Abstract:
Improvements in anticancer treatments, the ability to modify myelosuppression profiles, greater duration and intensity of immunosuppression, and the variety of available antimicrobial therapies have influenced the spectrum of pathogens associated with invasive fungal infection complicating treatment of hematological malignancies and hematopoietic stem cell transplantation. The approaches to the management of these infections encompass strategies of prevention for all those at risk, preemptive therapy based upon surrogates of infection before the onset of clinical disease, empirical therapy for patients with clinical evidence of early disease, and directed or targeted therapy for infected patients with established disease. Chemoprophylaxis is effective if applied to the highest risk patients over the duration of the risk. Preemptive strategies, while promising, have yet to be validated and linked to reliably predictive non-microbiological diagnostic techniques. Empirical antifungal therapy, as it is currently applied, now seems questionable. Patients with probable or proven invasive fungal infection still have suboptimal outcomes despite the availability of promising anti-fungal agents. Strategies examining the concept of dose-intensity and combination regimens require careful study and cannot yet be regarded as an acceptable standard of practice.
Insights
Managing invasive fungal infections in cancer patients is complex due to evolving treatments. Current empirical antifungal therapy shows suboptimal outcomes, necessitating further research into optimal strategies for high-risk individuals.
Area of Science:
- Mycology
- Hematology
- Oncology
- Infectious Diseases
Background:
- Advances in cancer therapy and immunosuppression have altered the landscape of invasive fungal infections (IFIs).
- Hematological malignancies and hematopoietic stem cell transplantation (HSCT) patients face a spectrum of fungal pathogens.
- The management of IFIs requires a multi-faceted approach, including prevention, preemptive, empirical, and targeted therapies.
Purpose of the Study:
- To review current strategies for managing invasive fungal infections in patients undergoing treatment for hematological malignancies and HSCT.
- To evaluate the effectiveness and limitations of different therapeutic approaches, including chemoprophylaxis, preemptive, empirical, and directed therapies.
- To highlight the suboptimal outcomes in patients with IFIs despite available antifungal agents and to identify areas for future research.
Main Methods:
- Literature review and synthesis of current evidence on invasive fungal infections in immunocompromised patients.
- Analysis of different management strategies: prevention, preemptive, empirical, and directed therapy.
- Critical appraisal of the efficacy and limitations of existing antifungal treatment paradigms.
Main Results:
- Chemoprophylaxis is effective in high-risk populations when applied appropriately.
- Preemptive strategies show promise but require validation with reliable diagnostic tools.
- Current empirical antifungal therapy yields suboptimal outcomes, indicating a need for reassessment.
- Despite novel antifungal agents, patients with probable or proven IFIs still experience poor outcomes.
- Dose-intensity and combination regimens require further investigation and are not yet standard practice.
Conclusions:
- The evolving nature of IFIs in immunocompromised patients necessitates adaptive management strategies.
- Current empirical antifungal approaches require re-evaluation due to suboptimal patient outcomes.
- Further research into optimized dosing, combination therapies, and validated diagnostic tools for preemptive strategies is crucial for improving IFI management.
Related Concept Videos
Antifungal Agents
Cryptococcal Meningitis
Fungal Phylum Ascomycota
Fungal Group Zygomycota
Overview of Fungi
Candidiasis

